The Accelerating Clinical Trials (ACT) consortium, through an independent, international review panel, has selected CanReview to set up, initiate, and conduct a pan-Canadian single REB review and approval process with strict timelines.
Currently, researchers who wish to conduct a multi-centre randomized controlled trial (RCT) across Canada are required to get multiple research ethics board (REB) approvals across the different research centres. As part of Canada’s mandate to improve the ecosystem for conducting clinical trials in Canada, ACT held an open competition to select a group to set up and run a sustainable pan-Canadian, distributive, single REB review and approval process with strict timelines for the initiation and conduct of multi-centre RCTs in Canada.
Working collaboratively with Research Ethics Boards, research teams, Indigenous community members, institutions and sponsors, patients and family partners and many others, CanReview will co-develop a system that will:
- Improve efficiencies and study start-up times
- Increase Canada’s competitiveness in attracting global clinical trials
- Expand clinical trials to underserved and rural and remote locations
- Improve equitable access to trial participation
Read more about the selection process from the Accelerating Clinical Trials consortium here.